4551 Stock Overview
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Torii Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥3,960.00 |
| 52 Week High | JP¥4,370.00 |
| 52 Week Low | JP¥3,275.00 |
| Beta | 0.34 |
| 1 Month Change | -3.65% |
| 3 Month Change | 6.17% |
| 1 Year Change | 20.00% |
| 3 Year Change | 53.79% |
| 5 Year Change | 73.23% |
| Change since IPO | 7.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4551 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 2.7% | 5.9% | 2.2% |
| 1Y | 20.0% | 6.9% | 28.4% |
Return vs Industry: 4551 exceeded the JP Pharmaceuticals industry which returned 6.9% over the past year.
Return vs Market: 4551 underperformed the JP Market which returned 28.4% over the past year.
Price Volatility
| 4551 volatility | |
|---|---|
| 4551 Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4551 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4551's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1872 | 583 | Goichi Matsuda | www.torii.co.jp |
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE.
Torii Pharmaceutical Co., Ltd. Fundamentals Summary
| 4551 fundamental statistics | |
|---|---|
| Market cap | JP¥111.17b |
| Earnings (TTM) | JP¥5.29b |
| Revenue (TTM) | JP¥56.28b |
21.0x
P/E Ratio2.0x
P/S RatioIs 4551 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4551 income statement (TTM) | |
|---|---|
| Revenue | JP¥56.28b |
| Cost of Revenue | JP¥33.08b |
| Gross Profit | JP¥23.20b |
| Other Expenses | JP¥17.91b |
| Earnings | JP¥5.29b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 31, 2024
| Earnings per share (EPS) | 188.26 |
| Gross Margin | 41.22% |
| Net Profit Margin | 9.39% |
| Debt/Equity Ratio | 0% |
How did 4551 perform over the long term?
See historical performance and comparisonDividends
2.5%
Current Dividend Yieldn/a
Payout RatioDoes 4551 pay a reliable dividends?
See 4551 dividend history and benchmarks| Torii Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Jun 27 2024 |
| Dividend Pay Date | Sep 05 2024 |
| Days until Ex dividend | 54 days |
| Days until Dividend pay date | 124 days |
Does 4551 pay a reliable dividends?
See 4551 dividend history and benchmarks